Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polypeptide N-acetylgalactosaminyltransferase 5 (GALNT5)
- Target
- GALNT5
- Molecular classification
- Enzyme, Glycosyltransferase, Transferase
01
Overview
Polypeptide N-acetylgalactosaminyltransferase 5 (GALNT5) is a membrane-bound glycosyltransferase enzyme located in the Golgi apparatus, where it catalyzes the initial step in the mucin-type O-glycosylation of proteins by transferring an N-acetyl-D-galactosamine residue to serine or threonine residues on protein substrates[2][5]. GALNT5 is crucial for the biosynthesis of O-linked oligosaccharides and is associated with the regulation of tumor cell proliferation, migration, invasion, ferroptosis suppression, and modulation of immune/inflammatory pathways in cancers such as pancreatic adenocarcinoma[1][2]. Increased expression of GALNT5 correlates with poor prognosis and may serve as a therapeutic target and biomarker in multiple tumor types[1].
- Other names
- GalNAc-T5pp-GaNTase 5polypeptide GalNAc transferase 5protein-UDP acetylgalactosaminyltransferase 5UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 5GALNAC-T5GALNACT5UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5GALT5
02
Mechanism of action
Inhibition or knockdown of GALNT5 promotes ferroptosis and suppresses tumor proliferation, migration, and invasion[1].
03
Biological functions
Protein O-glycosylationRegulation of cell proliferationRegulation of cell migrationSuppression of ferroptosisModulation of immune microenvironment
04
Disease associations
CancerPancreatic adenocarcinomaCholangiocarcinomaColorectal cancerHepatoblastomaHepatocellular carcinoma
05
Safety considerations
Potential disruption of normal protein glycosylation in non-tumor tissuesEffects on immune and inflammatory pathways are not fully understood
06
Biomarkers
GALNT5 expression level (as a prognostic marker in several cancers including pancreatic adenocarcinoma)[1].
Beyond the preview
Go deeper on Polypeptide N-acetylgalactosaminyltransferase 5 (GALNT5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polypeptide N-acetylgalactosaminyltransferase 5 (GALNT5).